Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91

Pharmacological Research

Volumn 61, Issue 2, 2010, Pages 108-115

  Yeh, Teng Kuang ^a   Li, Chien Ming ^a   Chen, Ching Ping ^a   Chuu, Jiuun Jye ^a,b   Huang, Chen Lung ^a   Wang, Hsin Sheng ^a   Shen, Chien Chang ^a   Lee, Tien Yi ^a   Chang, Chi Yen ^a   Chang, Chung Ming ^a   Chao, Yu Sheng ^a   Lin, Chin Tarng ^c   Chang, Jang Yang ^a   Chen, Chiung Tong ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Anticancer activity; Camptothecin; DB 67; Lactone stability; Pharmacokinetics; Topoisomerase I

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DB 67; DB 91; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; LACTONE; SILATECAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; CANCER INHIBITION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STEADY STATE; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSOMES, LIVER; NEOPLASMS; ORGANOSILICON COMPOUNDS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73949141120     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.07.005     Document Type: Article

References (61)

1. Pizzolato J.F., and Saltz L.B. The camptothecins. Lancet 361 (2003) 2235-2242
2. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6 (2006) 789-802
3. Potmesil M., Hsiang Y.H., Liu L.F., Bank B., Grossberg H., Kirschenbaum S., et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48 (1988) 3537-3543
4. Husain I., Mohler J.L., Seigler H.F., and Besterman J.M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54 (1994) 539-546
5. Gupta R.S., Gupta R., Eng B., Lock R.B., Ross W.E., Hertzberg R.P., et al. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48 (1988) 6404-6410
6. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicholas A.W., Liu L.F., et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246 (1989) 1046-1048
7. Giovanella B.C., Hinz H.R., Kozielski A.J., Stehlin Jr. J.S., Silber R., and Potmesil M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51 (1991) 3052-3055
8. Giovanella B.C., Harris N., Mendoze J., Cao Z., Liehr J., and Stehlin J.S. Dependence of anticancer activity of camptothecins on maintaining their lactone function. Ann NY Acad Sci 922 (2000) 27-35
9. Hsiang Y.H., and Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48 (1988) 1722-1726
10. Hertzberg R.P., Caranfa M.J., Holden K.G., Jakas D.R., Gallagher G., Mattern M.R., et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32 (1989) 715-720
11. Burke T.G., and Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37 (1994) 40-46
12. Mi Z., and Burke T.G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33 (1994) 10325-10336
13. Burke T.G., and Mi Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212 (1993) 285-287
14. Mi Z., Malak H., and Burke T.G. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 34 (1995) 13722-13728
15. Bom D., Curran D.P., Kruszewski S., Zimmer S.G., Thompson-Strode J., Kohlhagen G., et al. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43 (2000) 3970-3980
16. Bom D., Curran D.P., Zhang J., Zimmer S.G., Bevins R., Kruszewski S., et al. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Rel 74 (2001) 325-333
17. Bom D., Curran D.P., Chavan A.J., Kruszewski S., Zimmer S.G., Fraley K.A., et al. Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J Med Chem 42 (1999) 3018-3022
18. Chen A., Shih S., Garriques L., Rothenberg M., Hsiao M., and Curran D.P. Silatecan DB-67 is a novel DNA topoisomerase 1-targeted radiation sensitizer. Mol Cancer Ther 4 (2005) 317-324
19. Pollack I.F., Erff M., Bom D., Burke T.G., Strode J.T., and Curran D.P. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res 59 (1999) 4898-4905
20. Warner D.L., and Burke T.G. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B: Biomed Sci Appl 691 (1997) 161-171
21. Newton D.J., Wang R.W., and Lu A.Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23 (1995) 154-158
22. Chu I., Favreau L., Soares T., Lin C., and Nomeir A.A. Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes. Rapid Commun Mass Spectrom 14 (2000) 207-214
23. Chollet D.F., Goumaz L., Renard A., Montay G., Vernillet L., Arnera V., et al. Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography. J Chromatogr B 718 (1998) 163-175
24. Kaneda N., Nagata H., Furuta T., and Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50 (1990) 1715-1720
25. Kuo C.C., Hsieh H.P., Pan W.Y., Chen C.P., Liou J.P., Lee S.J., et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 64 (2004) 4621-4628
26. Tien H.F., Lee F.Y., Chuang S.M., and Lin C.T. Cytogenetic characterization of a nasopharyngeal carcinoma cell line and its subline. Cancer Genet Cytogenet 49 (1990) 31-36
27. Chuu J.J., Liu J.M., Tsou M.H., Huang C.L., Chen C.P., Wang H.S., et al. Effects of paclitaxel and doxorubicin in histocultures of hepatocellular carcinomas. J Biomed Sci 14 (2007) 233-244
28. Kudelka A.P., Tresukosol D., Edwards C.L., Freedman R.S., Levenback C., Chantarawiroj P., et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14 (1996) 1552-1557
29. Pitot H.C., Wender D.B., O'Connell M.J., Schroeder G., Goldberg R.M., Rubin J., et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15 (1997) 2910-2919
30. Kurose A., Tanaka T., Huang X., Halicka H.D., Traganos F., Dai W., et al. Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis. Cytometry A 68 (2005) 1-9
31. Yu Y., Wang L.S., Shen S.M., Xia L., Zhang L., Zhu Y.S., et al. Subcellular proteome analysis of camptothecin analogue NSC606985-treated acute myeloid leukemic cells. J Proteome Res 6 (2007) 3808-3818
32. Ravi R., Jain A.J., Schulick R.D., Pham V., Prouser T.S., Allen H., et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 64 (2004) 9105-9114
33. Tse A.N., Rendahl K.G., Sheikh T., Cheema H., Aardalen K., Embry M., et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 13 (2007) 591-602
34. Ju D.S., Kim M.J., Bae J.H., Song H.S., Chung B.S., Lee M.K., et al. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells. Cancer Lett 252 (2007) 75-85
35. Song M.G., Gao S.M., Du K.M., Xu M., Yu Y., Zhou Y.H., et al. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms. Blood 105 (2005) 3714-3721
36. Cimmino G., Pepe S., Laus G., Chianese M., Prece D., Penitente R., et al. Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines. Pharmacol Res 55 (2007) 49-56
37. Yang X., Luo P., Yang B., and He Q. Antiangiogenesis response of endothelial cells to the antitumour drug 10-methoxy-9-nitrocamptothecin. Pharmacol Res 54 (2006) 334-340
38. Ji Y., Hayashi K., Amoh Y., Tsuji K., Yamauchi K., Yamamoto N., et al. The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. Anticancer Res 27 (2007) 713-718
39. Huang M., Gao H., Chen Y., Zhu H., Cai Y., Zhang X., et al. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res 13 (2007) 1298-1307
40. Beretta G.L., Petrangolini G., De Cesare M., Pratesi G., Perego P., Tinelli S., et al. Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring. Cancer Res 66 (2006) 10976-10982
41. Sessa C., Cresta S., Cerny T., Baselga J., Rota Caremoli E., et al. Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol 18 (2007) 561-568
42. Lee D., Kim S.W., Suh C., Lee J.S., Lee J., Lee S.J., et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 19 (2008) 123-127
43. Scott L., Soepenberg O., Verweij J., de Jonge M.J., Th Planting A.S., McGovern D., et al. A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Ann Oncol 18 (2007) 569-575
44. Dark G.G., Calvert A.H., Grimshaw R., Poole C., Swenerton K., Kaye S., et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 23 (2005) 1859-1866
45. Daud A., Valkov N., Centeno B., Derderian J., Sullivan P., Munster P., et al. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res 11 (2005) 3009-3016
46. Lavergne O., Lesueur-Ginot L., Pla Rodas F., Kasprzyk P.G., Pommier J., Demarquay D., et al. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem 41 (1998) 5410-5419
47. Lesueur-Ginot L., Demarquay D., Kiss R., Kasprzyk P., Dassonneville L., Bailly C., et al. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res 59 (1999) 2939-2943
48. Lavergne O., Demarquay D., kasprzyk P.G., and Bigg D.C. Homocamptothecins: E-ring modified CPT analogues. Ann NY Acad Sci 922 (2000) 100-101
49. Gounder M.K., Nazar A.S., Saleem A., Pungaliya P., Kulkarni D., Versace R., et al. Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan. Invest New Drugs 26 (2008) 205-213
50. Rowinsky E.K., Grochow L.B., Hendricks C.B., Ettinger D.S., Forastiere A.A., Hurowitz L.A., et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10 (1992) 647-656
51. Kollmannsberger C., Mross K., Jakob A., Kanz L., and Bokemeyer C. Topotecan-a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56 (1999) 1-12
52. Supko J.G., and Malspeis L. Pharmacokinetics of the 9-amino and 10, 11-methylenedioxy derivatives of camptothecin in mice. Cancer Res 53 (1993) 3062-3069
53. Davies B., and Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 10 (1993) 1093-1095
54. Verweij J., Lund B., Beijnen J., Planting A., de Boer-Dennert M., Koier I., et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4 (1993) 673-678
55. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54 (1994) 987-992
56. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51 (1999) 691-743
57. Sung C., Blaney S.M., Cole D.E., Balis F.M., and Dedrick R.L. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 54 (1994) 5118-5122
58. Zamboni W.C., Egorin M.J., Van Echo D.A., Day R.S., Meisenberg B.R., Brooks S.E., et al. Pharmacokinetic and pharmacodynamic study of the combination of docetaxol and topotecan in patients with solid tumors. J Clin Oncol 18 (2000) 3288-3294
59. Singh B., Li R., Xu L., Poluri A., Patel S., Shaha A.R., et al. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24 (2002) 437-442
60. Liu X., Lin J., Bao Y., Lin X., and An L. Camptothecin-mediated apoptosis and antiproliferation effect is accompanied by down-regulation of telomerase activity in HaCaT cells. J Dermatol Sci 42 (2006) 262-264
61. Lin J., Liu X., Bao Y., Hou S., An L., and Lin X. Effects of isocamptothecin, a novel camptothecin analogue, on proliferation, apoptosis and telomerase activity in HaCaT cells. Exp Dermatol 17 (2008) 530-536